Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015

Corporate Breaking News

Home : Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015

Jan 22 2020	Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015
STOCKHOLM, Jan. 22, 2020 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has now completed the expert evaluation of the results from the North American Phase 3-study. The analysis conducted with key opinion leaders (KOLs) has confirmed the validity of the data presented in December 2019 and...


Source:https://www.prnewswire.com:443/news-releases/expert-evaluation-clarifies-phase-3-results-and-provides-strong-support-for-mob-015-300990988.html

Related News
» PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period » Hansa Biopharma to Host Conference Call to Provide Year-End report 2019 and Business Update